ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 018,44
0,76%
Dow Jones
38 675,68
1,18%
DAX
18 159,88
0,92%
Brent Oil
83,555
0,52%
Bitcoin
64 290,00
0,45%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Hoth Therapeutics Inc (HOTH)

  7. Hoth Therapeutics Inc (HOTH) Actualités

HOTH Hoth Therapeutics Inc

1,21
0,00 (0,00%)
Avant marché
Dernière mise à jour : 12:40:39
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Hoth Therapeutics Inc HOTH NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 1,21 12:40:39
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
1,21
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
01/5/202414:00PRNUSHoth Therapeutics to Attend EF Hutton Annual Global..
27/3/202419:00PRNUSHoth Therapeutics Announces Exercise of Warrants for $4.2..
27/3/202413:27PRNUSHoth Therapeutics' Wholly Owned Subsidiary Merveille.ai,..
19/3/202413:21PRNUSHoth Therapeutics Announces Positive Data In Completed Study..
29/2/202414:38PRNUSHoth Therapeutics Retains Venable LLP to Expand Its Patent..
26/2/202414:11PRNUSHoth Therapeutics Engages Altasciences to Perform Key Study..
13/2/202417:45PRNUSHoth Therapeutics to Attend BIO CEO and Investor Conference,..
18/1/202414:20PRNUSHoth Therapeutics Announces it Received FDA Approval to..
09/1/202421:03EDGAR2Form 8-K - Current report
08/1/202423:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202423:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202423:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202423:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/12/202314:21PRNUSHoth Therapeutics Announces Expansion of FDA Cleared..
05/12/202314:33PRNUSHoth Therapeutics Announces it Has Successfully Completed..
14/11/202314:37PRNUSHoth Therapeutics Announces Successful Completion of Pre-IND..
13/11/202322:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/11/202314:00PRNUSHoth Therapeutics to Present at NobleCon's 19th Annual..
05/10/202316:03PRNUSHoth Therapeutics Announces Merveille.ai Artificial..
05/10/202314:15EDGAR2Form 8-K - Current report
02/10/202314:33PRNUSFDA Grants Hoth Therapeutics Pre-IND Meeting for HT-KIT,..
15/9/202322:15EDGAR2Form 8-K - Current report
15/9/202320:38PRNUSHoth Therapeutics Announces Closing of $2.89 Million..
14/9/202323:24EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
13/9/202319:43PRNUSHoth Therapeutics Announces $2.89 Million Registered Direct..
13/9/202314:16PRNUSHoth Therapeutics Announces Positive Results Killing Cancer..
11/9/202316:04PRNUSHoth Therapeutics Announces FDA Accepts Pre-Investigational..
06/9/202314:12PRNUSHoth Therapeutics Announces Positive Final Results from..
21/8/202323:10EDGAR2Form 8-K - Current report
21/8/202323:00EDGAR2Form S-8 - Securities to be offered to employees in employee..
11/8/202322:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/8/202314:13PRNUSHoth Therapeutics Announces Positive Preclinical End Point..
25/7/202314:12PRNUSHoth Therapeutics Announces Major Milestone of First Patient..
19/7/202314:02PRNUSHoth Therapeutics Receives Protocol Approval for HT-001..
18/7/202322:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/7/202322:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/7/202322:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/7/202322:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202314:12PRNUSHoth Therapeutics Announces IRB Approval for FDA Cleared..
06/6/202314:02PRNUSHoth Therapeutics Announces Positive Preclinical Results of..
12/5/202314:38PRNUSHoth Therapeutics and Algorithm Sciences Terminate Letter of..

Dernières Valeurs Consultées

NASDAQ
HOTH
Hoth Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés